Brazilian OTC marketing potential for U.S. companies stressed by consultants.
This article was originally published in The Tan Sheet
Executive Summary
BRAZILIAN OTC MARKET OPPORTUNITIES ABOUND FOR U.S. COMPANIES due to the country's growing buying power and population, U.S. firms' marketing experience and the proximity of the region, IMS SelfMedication Europe VP William Quaeyhaegens declared at the Nonprescription Drug Manufacturers Association's annual conference in Palm Beach, Fla. March 19-22. U.S. companies hold a 25% share of the OTC market in Brazil, an amount that could easily be higher, Quaeyhaegens said. The session on the Brazilian OTC market was sponsored by NDMA's International Affairs Committee.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning